

# Journal of Visualized Experiments

## CRISPR-Cas9-mediated genome editing in the filamentous ascomycete *Huntiella omanensis*

--Manuscript Draft--

<b>Article Type:</b>	Invited Methods Article - JoVE Produced Video
<b>Manuscript Number:</b>	JoVE61367R2
<b>Full Title:</b>	CRISPR-Cas9-mediated genome editing in the filamentous ascomycete <i>Huntiella omanensis</i>
<b>Section/Category:</b>	JoVE Genetics
<b>Keywords:</b>	Genome editing; CRISPR-Cas9; RNP; Transformations; Sexual reproduction; Fungi; <i>Huntiella omanensis</i>
<b>Corresponding Author:</b>	Andrea Wilson University of Pretoria Pretoria, Gauteng SOUTH AFRICA
<b>Corresponding Author's Institution:</b>	University of Pretoria
<b>Corresponding Author E-Mail:</b>	andi.wilson@fabi.up.ac.za
<b>Order of Authors:</b>	Andrea Wilson Brenda D Wingfield
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	Pretoria, Gauteng, South Africa

**TITLE:**

CRISPR-Cas9-Mediated Genome Editing in the Filamentous Ascomycete *Huntia omanensis*

**AUTHORS AND AFFILIATIONS:**

Andi M. Wilson<sup>1,2</sup>, Brenda D. Wingfield<sup>1,2</sup>

<sup>1</sup>Department of Biochemistry, Genetics & Microbiology, University of Pretoria, Pretoria, South Africa

<sup>2</sup>Forestry & Agricultural Biotechnology Institute (FABI), University of Pretoria, Pretoria, South Africa

Email addresses of co-authors:

Brenda D. Wingfield (Brenda.wingfield@up.ac.za)

Corresponding author:

Andi M. Wilson (Andi.wilson@fabi.up.ac.za)

**KEYWORDS:**

Genome editing; CRISPR-Cas9; RNP; Transformations; Sexual reproduction; Fungi; *Huntia omanensis*

**SUMMARY:**

The CRISPR-Cas9 genome editing system is an easy-to-use genome editor that has been used in model and non-model species. Here we present a protein-based version of this system that was used to introduce a premature stop codon into a mating gene of a non-model filamentous ascomycete fungus.

**ABSTRACT:**

The CRISPR-Cas9 genome editing system is a molecular tool that can be used to introduce precise changes into the genomes of model and non-model species alike. This technology can be used for a variety of genome editing approaches, from gene knockouts and knockins to more specific changes like the introduction of a few nucleotides at a targeted location. Genome editing can be used for a multitude of applications, including the partial functional characterization of genes, the production of transgenic organisms and the development of diagnostic tools. Compared to previously available gene editing strategies, the CRISPR-Cas9 system has been shown to be easy to establish in new species and boasts high efficiency and specificity. The primary reason for this is that the editing tool uses an RNA molecule to target the gene or sequence of interest, making target molecule design straightforward, given that standard base pairing rules can be exploited. Similar to other genome editing systems, CRISPR-Cas9-based methods also require efficient and effective transformation protocols as well as access to good quality sequence data for the design of the targeting RNA and DNA molecules. Since the introduction of this system in 2013, it has been used to genetically engineer a variety of model species, including *Saccharomyces cerevisiae*, *Arabidopsis thaliana*, *Drosophila melanogaster* and *Mus musculus*. Subsequently, researchers working on non-model species



have taken advantage of the system and used it for the study of genes involved in processes as diverse as secondary metabolism in fungi, nematode growth and disease resistance in plants, among many others. This protocol detailed below describes the use of the CRISPR-Cas9 genome editing protocol for the truncation of a gene involved in the sexual cycle of *Huntia omanensis*, a filamentous ascomycete fungus belonging to the Ceratocystidaceae family.

## INTRODUCTION:

The increasing availability of high quality, fully assembled genomes and transcriptomes has greatly improved the ability to study a wide variety of biological processes in an array of organisms<sup>1</sup>. This is true of both model species as well as non-model species, many of which may offer a more diverse understanding of biological processes. These kinds of data can be used for gene discovery, the identification of transcription networks and both whole genome and transcriptome comparisons, each of which come with their own set of applications. However, while genes are being predicted, annotated and putatively linked to different functional pathways at a never-before-seen rate, the functional characterization of these genes remains behind, limited by the molecular toolkits available for many species. This is particularly the case for the non-model species, where genomic data is relatively easy to generate but where further molecular characterization has been near impossible<sup>1,2</sup>.

Partial characterization of the functions of specific genes important to the biology of fungal species can be achieved by either knockout or knockin experiments followed by phenotypic analysis of the mutant strains<sup>3</sup>. These two systems rely entirely on the availability of genetic engineering protocols, including, at minimum, a transformation system and a genetic editing system. There are a number of different transformation systems that have been developed in a variety of filamentous fungi<sup>4</sup>. Physical systems like those that rely on biolistics and electroporation have been developed in *Trichoderma harzianum*<sup>5</sup> and *Aspergillus niger*<sup>6</sup>, respectively. Systems that utilize chemicals such as calcium chloride or lithium acetate have been developed in *Neurospora crassa*<sup>7</sup>. Lastly, biological systems that rely on the use of *Agrobacterium tumefaciens* for transformation have been successfully used in *Ceratocystis albifundus*<sup>8</sup>.

In contrast to the availability of different transformation protocols, genome editing systems are less abundant. Many of the traditional functional characterization experiments conducted in filamentous fungi utilized a split marker knockout construct in the form of a selectable marker flanked by regions of homology to the target region or gene in the genome<sup>3</sup>. The method relies on homology directed (HR) DNA repair, which facilitates homologous recombination between the knockout construct and the region of interest. This recombination event results in the replacement of the gene of interest with the sequence of the selectable marker. Unfortunately, while this was successful in many species including *Cercospora nicotianae*<sup>10</sup>, *Aspergillus fumigatus*<sup>11</sup> and *Grosmannia clavigera*<sup>12</sup>, the rates of homologous recombination are highly variable across different fungal species, making this an inefficient and sometimes unusable protocol in certain species<sup>3</sup>.

Other genome editing systems, including those that make use of zinc-finger nucleases (ZFNs)

and transcription activator-like effector nucleases (TALENs) represented a great improvement on the older systems, particularly given their abilities to make specific and targeted changes<sup>13</sup>. Both ZFNs and TALENs are comprised of a nuclease protein and a protein that is capable of recognizing specific nucleotide sequences<sup>13</sup>. Upon recognition, the nuclease induces a double stranded DNA break that can facilitate the introduction of specific mutations. In order to bring about genome changes, the protein region that recognizes the nucleotide sequence needs to be specifically designed for each experiment. Because of this reliance on protein-nucleic acid interactions to guide the editing, designing and producing the targeting molecules for each knockout or knockin experiment is difficult and labor intensive<sup>14,15</sup>. Illustrative of these challenges, very few filamentous fungi have been subjected to genome editing using these systems. One example is the TALENs-based system that was developed in the rice blast fungus, *Magnaporthe oryzae*<sup>16</sup>.

Arguably the greatest revolution to the field of genome editing was the discovery and subsequent development of the CRISPR-Cas9 system- a genome editor that allows for the targeted cleavage of a sequence of interest by an endonuclease that is guided by an RNA molecule. This was a huge improvement on the previously developed genome editors that relied on protein-nucleic acid interactions as the major advantage of the CRISPR-Cas9 system is that it relies on an RNA molecule to target the region of interest. This means that the system relies on an RNA-DNA interaction and thus standard base pairing rules can be exploited when designing each experiment<sup>15</sup>.

The CRISPR-Cas9 system as detailed here is comprised of three major components: a single guide RNA (sgRNA), the Cas9 enzyme and a donor DNA (dDNA)<sup>17</sup>. The sgRNA is composed of a 20 nucleotide region called the protospacer as well as a longer region called the scaffold<sup>18</sup>. The protospacer region is used to guide the editing system to the target region and is thus redesigned for each experiment. The scaffold is the region of RNA that physically binds to the Cas9 enzyme to form the ribonucleoprotein (RNP) and is thus identical regardless of the region to be targeted. The Cas9 enzyme physically facilitates the cleavage of the target DNA, using the protospacer as a guide to identify this region<sup>19</sup>. The last component, the dDNA, is optional and its use depends on the particular experiment<sup>20</sup>. The dDNA harbors sequence data that should specifically be inserted into the region being cut by the Cas9 enzyme, and is thus ideal for gene knockin experiments where a gene is being introduced into the genome or for gene knockout experiments where an antibiotic resistance gene or other selectable marker is being introduced to replace the gene of interest. The dDNA can also be designed in such a way as to introduce novel sequences into the genome. For example, as detailed below, it is possible to introduce an in-frame stop codon into a particular region in the gene of interest when a particular gene truncation is required<sup>21</sup>. Other applications include the mutation of specific regions of the gene, such as a functional domain<sup>22</sup>, or the introduction of a tagging sequence<sup>23</sup>.

A major benefit of using the CRISPR-Cas9 system is its versatility<sup>24</sup>. One example of this adaptability is that the Cas9 enzyme can be introduced into the host cell in one of its three forms- DNA, RNA or protein- depending on the particular transformation system being used. When introduced in DNA form, the *cas9* gene is often included on a plasmid along with a

selectable marker, a cassette to express the sgRNA and, if necessary, a cassette encoding the dDNA sequence<sup>25</sup>. The primary advantage of this system is that only a single construct needs to be transformed into the cell and successful transformation ensures that all the necessary components for CRISPR-Cas9-mediated genome editing are present. However, this method relies on the availability of an expression system for the host species. For Cas9 to successfully induce DNA damage, it needs to be expressed at high levels, and thus, a suitable and potentially specific-specific promoter is required. For non-model species where such promoters have not yet been developed, this may be a detracting factor and thus the ability to introduce Cas9 in RNA or protein form may be a more attractive option. The introduction of RNA into the cell brings its own challenges- particularly in that RNA is unstable and may not survive the transformation process. Furthermore, when introduced in either DNA or RNA form, the Cas9 gene sequence may need to be codon-optimized for use in the particular host system<sup>17</sup>. For example, the *cas9* gene from *Streptococcus pyogenes* may not work in a mammalian host cell and a *cas9* gene that has been codon-optimized for use in a mammalian cell may not work in a plant cell. All of these challenges can be overcome using the protein form of Cas9, which, together with the sgRNA, can be assembled into an RNP and transformed into the host cell<sup>26,27</sup>. This system does not rely on any endogenous expression system or codon optimization and should thus work in the majority of non-model species. The disadvantage of the protein-based system is that it is not compatible with DNA-based transformation systems like *Agrobacterium*-mediated transfer. Thus, for the protein-based method to work, a transformation protocol such as those that rely on protoplasts or biolistics needs to be available. This RNP-based system has been successfully used in the filamentous fungi, *Fusarium oxysporum*<sup>26</sup> and *Mucor circinelloides*<sup>27</sup>.

*Huntia omanensis*, a member of the Ceratocystidaceae family, is a cosmopolitan fungus often found on freshly wounded woody plants<sup>28</sup>. While high quality genome and transcriptome data are available for this species<sup>28-30</sup>, no transformation or genome editing protocols have been developed. To date, research on *H. omanensis* has focused on the underlying genetic components of its sexual cycle<sup>29,31</sup>. This fungus exhibits a typical heterothallic sexual cycle, with sexual reproduction occurring exclusively between isolates of the MAT1 and MAT2 mating types<sup>31</sup>. In contrast, MAT2 isolates of the closely related *Huntia moniliformis* are capable of independent sexual reproduction and complete a sexual cycle in the absence of a MAT1 partner<sup>31</sup>. This difference in sexual capabilities is thought to be, at least partly, due to a major difference in the mating gene, *MAT1-2-7*, where *H. omanensis* harbors a full length and intact copy, while the gene is severely truncated in *H. moniliformis*<sup>29,31</sup>. To further characterize the role of this gene in sexual reproduction, the *MAT1-2-7* gene of *H. omanensis* was truncated to mimic the truncation seen in *H. moniliformis*<sup>21</sup>.

The protocol below details the transformation of *H. omanensis* and the truncation of the *MAT1-2-7* gene using a protein-based version of the CRISPR-Cas9 genome editing system. This protocol was developed after the approaches of homologous recombination-based gene replacement and plasmid-based CRISPR-Cas9 genome editing were unsuccessful.

## PROTOCOL:

## 1. Design and synthesis of the sgRNA

1.1 To identify potential protospacer regions that will form part of the sgRNA, manually search through the gene-of-interest for 5' NGG 3' triplets, using the search function in which ever program is being used. Annotate these triplets as PAM sequences.

NOTE: Various software programs are available that search for and annotate the potential PAM and protospacer sequences.

1.1.1 Select the 20 bp upstream of each of the identified PAM sequences and annotate these sequences as potential protospacers.

1.2 To decide on a single protospacer, perform the following filtering steps to discard low quality sequences.

1.2.1. To test for the specificity of the potential protospacers, combine the PAM sequence and protospacer into a single sequence and use it as a BLASTn query against the entire genome. Discard any protospacers that show similarity to any region in the genome other than the target region (**Figure 1A**).

1.2.2. To ensure that the RNA molecule will fold into the correct 3D structure for binding to the Cas9 enzyme, create a combined sequence including the protospacer and the scaffold sequence specific to the Cas9 enzyme.

1.2.2.1. Upload each of the combined protospacer-scaffold sequences into an RNA secondary structure prediction tool (**Table of Materials**).

1.2.2.2. Analyze the results by comparing the minimal free energy and centroid secondary structures.

NOTE: Ideal protospacer candidates will have identical minimal free energy and centroid secondary structures (f). Both secondary structures should be comprised of three stem loops, interrupted by five ring structures. The structures should also exhibit high binding probabilities (indicated in red) throughout the entire structure, except for the region representing the protospacer (**Figure 1B**). The actual energy values are not relevant.

1.2.3. Choose a final candidate from those that passed the above filtering steps by selecting the candidate that is closest to the specific region being targeted.

1.3. To synthesize the sgRNA as a single RNA molecule, use an sgRNA synthesis kit (**Table of Materials**) compatible with the particular Cas9 enzyme that will be used (e.g., Cas9 from *Streptococcus pyogenes*).

NOTE: The following steps may be dependent on the sgRNA synthesis kit used. In the event that a different kit is used, follow the manufacturer's instructions. Alternatively, the sgRNA can be ordered pre-synthesized. When working with RNA, use nuclease-free reagents and disposables.

1.3.1. If the 20 bp protospacer chosen in step 1.3 above does not harbor a G at the 5' end, add a G to this region.

1.3.2. Add the T7 promoter sequence to the 5' end of the target sequence. This sequence is standard and is 5' TTCTAATACGACTCACTATAG 3'.

1.3.3. Add a 14 nt overlap sequence to the 3' end of the target sequence. This sequence is kit-specific and is 5' GTTTTAGAGCTAGA 3' for the kit used here.

1.3.4. Order the resulting fragment 5' TTCTAATACGACTCACTATAG(N)<sub>20</sub> GTTTTAGAGCTAGA, with (N)<sub>20</sub> representing the selected protospacer presynthesized (**Table of Materials**).

1.3.5. In accordance with the manufacturer's protocol (**Table of Materials**), combine the following reagents at room temperature: 2 µL of water, 10 µL of reaction buffer, 5 µL of synthesized protospacer sequence, 1 µL of 0.1 M DTT and 2 µL of transcriptase enzyme.

1.3.6. Incubate this solution at 37 °C for 30 min and transfer to ice.

1.3.7. Add 30 µL of water and 2 µL of DNase I, mix and incubate at 37 °C for a further 15 min.

1.3.8. Visualize the resulting sgRNA on a 2% agarose gel.

## 2. Testing the in vitro Cleavage Ability of the sgRNA

NOTE: This step is optional but is recommended.

2.1. Design primers that will amplify a fragment harboring the sequence of the site that the chosen sgRNA will target and amplify the region using a standard DNA polymerase.

NOTE: If possible, design the primers in such a way that cleavage at the target site will produce two fragments of very different sizes that can easily be distinguished from one another on a standard agarose gel.

2.2. Assemble the combined sgRNA-Cas9 ribonucleoprotein (RNP) by incubating a solution comprised of 30 nM sgRNA as synthesized above, 30 nM Cas9 protein, 10x reaction buffer and 10 µL of water at 25 °C for 10 min.

2.3. Test the cleavage ability of the sgRNA by adding the PCR product of the target region into the RNP solution to a final concentration of 3 nM.

265 2.3.1. Incubate the solution at 37 °C for 15 min.

266  
267 2.3.2. Add 3 µg of proteinase K and 2 µg of RNase to the solution to stop the cleavage reaction  
268 and incubate at room temperature for 10 min.

269  
270 2.3.3. Visualize the resulting DNA fragments on a 2% agarose gel. The sgRNA is suitable for in  
271 vivo experimentation if two bands of the expected size are observed on the gel.

### 272 273 **3. Design and synthesis of the dDNA**

274  
275 3.1. Design the dDNA to be comprised of three regions- 5' and 3' regions with complementarity  
276 to the genomic region being targeted and a middle region harboring a selectable marker (**Table**  
277 **of Materials, Figure 2**).

278  
279 NOTE: Other specific sequences can also be added to this selectable marker. For this particular  
280 experiment, a stop codon sequence (5' TGA 3') was added just before the selectable marker,  
281 thereby introducing an in-frame stop codon into the gene. The dDNA can be ordered  
282 presynthesized. Alternatively, the dDNA can be amplified and assembled using a stepwise,  
283 overlap PCR approach as detailed below.

284  
285 3.1.1. Design primers to amplify approximately 800 bp of the 5' and 3' flanking regions. Add 20  
286 nt of sequence that is complementary to the selectable marker's sequence to the 5' region's  
287 reverse primer and 3' region's forward primer.

288  
289 3.1.2. Design primers that amplify the selectable marker, ensuring that the amplified product  
290 harbors the resistance gene as well as a promoter known to work in the species of interest.

291  
292 3.2. Using a high-fidelity DNA polymerase (**Table of Materials**), amplify the three dDNA regions.  
293 Amplify the 5' and 3' regions from the gDNA of the organism being edited. Amplify the  
294 selectable marker from a relevant source.

295  
296 3.2.1. In a single reaction, combine the amplified 5' region with the selectable marker and,  
297 using a long-range, high-fidelity DNA polymerase, amplify the entire region.

298  
299 3.2.2. In a second single reaction, combine the amplified 3' region with the selectable marker  
300 and, using a long-range, high-fidelity DNA polymerase, amplify the entire region.

301  
302 3.2.3. Finally, combine the two preceding PCR products into a single reaction and amplify the  
303 entire dDNA sequence with a long-range, high-fidelity DNA polymerase.

304  
305 3.2.4. Visualize the DNA fragment on a 1% agarose gel. In the event that two or more fragments  
306 are produced, purify the correctly sized fragment from the gel using a gel purification kit.

### 307 308 **4. Extraction of protoplasts**

4.1 To produce conidia, inoculate 200 mL of fresh 2% malt extract broth (MEB) in a 500 mL flask with a 1 cm x 1 cm mycelia-covered agar block .

NOTE: Not all fungi are able to produce conidia. In that case, mycelia can also be used. This will typically require higher concentrations of lysing enzyme further in the protocol.

4.1.1. Incubate the liquid culture in a shaking incubator at 25 °C with shaking at 120 rpm for 24 - 48 h.

NOTE: This incubation time has been optimized for *H. omanensis*. This will need to be optimized for other species.

4.1.2. To harvest the conidia; filter the liquid culture through a layer of sterile laboratory cloth (e.g., Miracloth), transfer the conidial suspension into 50 mL centrifuge tubes and centrifuge at 3,220 x *g* at 4 °C for 10 min. Discard the supernatant.

4.1.3. Resuspend the conidia in 5 mL of water and pipette 10 µL of the conidia solution onto a microscope slide and cover with a coverslip. Visualize using a compound microscope under 40x magnification to ensure only conidia have been recovered (**Figure 3A**).

4.1.4. In a 500 mL flask, inoculate 200 mL of fresh 1% MEB with the total volume of resuspended conidia.

4.1.5. Incubate the liquid culture in a shaking incubator at 25 °C with shaking at 120 rpm for up to 12 h.

NOTE: This incubation time has been optimized for *H. omanensis*. This will need to be optimized for other species.

4.1.6. To harvest the germlings, transfer the liquid culture into 50 mL centrifuge tubes and centrifuge at 3,220 x *g* at 4 °C for 10 min. Discard the supernatant.

4.1.7. Resuspend the germlings in up to 10 mL of 1 M sorbitol.

4.1.8. Pipette 10 µL of the germling solution onto a microscope slide and cover with a coverslip. Visualize using a compound microscope under 40x magnification to ensure only germlings have been recovered (**Figure 3B**).

NOTE: The protocol can be paused here. Store germlings in 1 M sorbitol at -80 °C.

4.2 To lyse the cell walls of the young germlings and release the protoplasts, add 1 mL of the germling suspension to 9 mL of lysing enzyme at various concentrations in a sterile 50 mL flask.

NOTE: Different enzyme concentrations and incubation times are used and can be found in **Table 1**. The enzymes and concentrations are also likely to vary depending on the fungus and will need to be optimized for each species.

4.2.1 Incubate the spore-enzyme solution in a shaking incubator at 25 °C with shaking at 80 rpm for 2 to 3 h.

4.2.2. Filter the protoplast solution through a layer of sterile laboratory cloth and collect the protoplasts by centrifugation at 1,810 x *g* at 4 °C for 10 min. Discard the supernatant.

NOTE: Protoplasts are cells without cell walls and are thus very sensitive to mechanical disruption. Be sure to handle them carefully, particularly when pipetting.

4.2.3. Carefully resuspend the protoplast pellet in 200 µL of STC buffer (**Table of Materials**).

4.2.4. Pipette 10 µL of the protoplast solution onto a microscope slide and cover with a coverslip. Visualize using a compound microscope under 40x magnification to ensure only protoplasts have been recovered (**Figure 3C**).

4.2.5 Using a hemocytometer, count and calculate the number of protoplasts generated in the above steps. Dilute the protoplast solution into aliquots containing approximately  $5 \times 10^6$  protoplasts.

NOTE: The protocol can be paused here. Store protoplasts in STC buffer at -80 °C.

## 5. Protoplast and PEG-assisted transformation and transformant recovery

5.1. To begin the transformation, combine approximately  $5 \times 10^6$  protoplasts with a single volume of the RNP solution and approximately 6 µg of the dDNA fragment.

NOTE: Protoplasts are very sensitive to mechanical disruption. Be sure to handle them carefully, particularly when pipetting.

5.1.1. Using a pipette, slowly drip 1 mL of a freshly prepared 30% PTC solution onto the protoplast solution and incubate the solution at room temperature for 20 min.

NOTE: This step is a sensitive and very important step. Make sure to use freshly prepared PTC solution and drop the solution over the cells as slowly and evenly as possible, creating a hydrophobic layer across the cell surface.

5.1.2. Add 5 mL of osmotic control medium (OCM) to the protoplast solution and pipette slowly and gently to ensure the solution is thoroughly mixed.

5.1.3. Incubate the protoplast solution in a shaking incubator at 25 °C with shaking at 80 rpm



overnight.

5.2. To select the transformed isolates, divide the solution into 5 empty 60 mm culture plates.

5.2.2. Add 10 mL of OCM agar supplemented with 30 µg/mL hygromycin B to each culture plate and slowly rotate each plate to mix thoroughly.

5.2.3. Allow the first layer of agar to set before adding 10 mL of osmotic control medium agar supplemented with 40 µg/mL hygromycin B.

5.2.4 Allow the second layer of agar to set and incubate the cultures at 25 °C until single isolates can be seen growing through both layers of agar.

5.3. To recover successfully transformed isolates, transfer the individual isolates capable of growth through the agar layer supplemented with 40 µg/mL hygromycin B to fresh malt extract agar (MEA) plates supplemented with 50 µg/mL hygromycin B (MEA-50).

5.3.1. Incubate the fresh cultures at 25 °C for 5 days, checking daily for growth. Cultures capable of sustained growth on this media have successfully been transformed and can be used for further study.

## 6. Confirmation of the integration and stability of the dDNA

6.1. In order to confirm that the dDNA has been integrated into the genome at the target region, design primers that flank the predicted 5' and 3' insert sites (**Figure 2**).

6.1.1. Perform two PCRs using these two primer sets and a high-fidelity DNA polymerase. If both PCRs yield amplicons of expected size and sequence, the dDNA was successfully integrated into the target region. Then, assess the mutant stain for stable integration of the dDNA.

6.2. In order to confirm that the dDNA has been stably integrated into the genome and will be maintained during vegetative growth, perform a media transfer test.

6.2.1. Transfer a block of mycelial-covered agar from an actively growing mutant isolate on MEA-50 medium to unsupplemented MEA medium. Incubate at 25 °C for 3 days.

6.2.2. Transfer a block of mycelia-covered agar from the isolate growing on MEA medium to MEA-50 medium. Incubate at 25 °C for 3 days.

6.2.3. Repeat this process, transferring actively growing mycelia from supplemented to unsupplemented medium for at least four rounds.

NOTE: If the isolate is capable of sustained growth on MEA-50 medium after many transfers, the dDNA has been stably integrated into the genome and can be maintained through

vegetative growth. The mutant strain can be assessed for the presence of only a single copy of the integrated dDNA.

6.3. In order to confirm that the dDNA has been integrated into the genome at a single location, perform a Southern blot analysis.

6.3.1. Digest a total of 30 µg of gDNA from each mutant strain using *HindIII* and *EcoRI* restriction enzymes in accordance with manufacturer's protocols.

NOTE: While the choice of restriction enzyme is up to the researcher, ensure that the restriction enzyme's recognition site is not present in the dDNA sequence.

6.3.2. Separate the digested gDNA on a 0.75% agarose gel and transfer the DNA onto a nylon membrane using standard procedures<sup>32</sup>.

6.3.3. Subject the membrane to hybridization using a probe targeting the dDNA sequence.

6.3.3.1 Design primers to amplify a short (300 bp) region of the dDNA.

6.3.3.2. Using these primers, synthesize the probe using a PCR DIG labeling mix.

6.3.3.3. Use the newly synthesized probe for membrane hybridization, treatment and visualization using standard procedures<sup>32</sup>. If only a single band is seen in each lane, the dDNA is present at only a single location in the genome. The mutant strain can now be used for further phenotypic analysis and functional characterization experiments.

## 7. Phenotypic analysis of the mutant strains

7.1. Conduct mating experiments to determine whether the disruption of the *MAT* gene had an effect on the sexual capabilities of the fungus being studied.

NOTE: This step is dependent on the particular gene and species being studied. In this case, the gene being targeting is thought to be involved in sexual reproduction and thus mating tests were conducted. If the gene was thought, for example, to be involved in asexual reproduction, then something like conidial production could be measured.

7.1.1. In order to test the heterothallic capabilities of the mutant strain, co-inoculate fresh MEA medium with a mutant strain as well as a strain of opposite mating type. In the case of *H. omanensis*, keep the lids of the plates closed, but not sealed and incubate at room temperature for 7 days. Visually assess for the production of sexual structures.

7.1.2. In order to test the homothallic capabilities of the mutant strain, inoculate fresh MEA medium with a mutant strain. In the case of *H. omanensis*, keep the lids of the plates closed, but not sealed and incubate at room temperature for 7 days. Visually assess for the production

of sexual structures.

7.2. Conduct growth rate experiments to determine whether the disruption of the *MAT* gene had an effect on the growth rate of the fungus being studied.

7.2.1 Create mycelial-covered agar plugs from the actively growing edge of cultures of the mutant and wildtype strains by inserting the back side of a large, sterile pipette tip into the agar.

7.2.2. Inoculate fresh MEA medium with these agar plugs. Ensure that at least three replicates per each culture type are made.

7.2.3. After 3 days of growth at 20 °C, measure the growth on two perpendicular diameters.

7.2.4. Compare the data from the wildtype and mutant strains.

#### REPRESENTATIVE RESULTS:

The protocol described above facilitated the introduction of a premature stop codon into a mating gene from the non-model ascomycete, *H. omanensis*. This process utilized a version of the CRISPR-Cas9 genome editing system and as such one of the most important steps in this protocol is the design and synthesis of a high quality sgRNA. **Figure 1** shows how this molecule was designed in such a way that it A) specifically targets the gene of interest and shows little similarity to other regions in the genome and B) folds correctly in order to bind with the Cas9 protein. The sgRNA must also be capable of effectively cleaving the target region. The ability of the sgRNA to target and allow for the cleavage of the target region was conducted in vitro, yielding two products of the expected size.

Once successful transformation has taken place, it is important to ensure that the dDNA has integrated into the genome only once and in the expected place. **Figure 2** illustrates the design of PCR primers that target the insertion sites, which can be used to screen the potential transformants for the correct integration site. By designing primers that flank the 5' and 3' insertion sites, amplification is only possible if the dDNA is inserted at the correct region. **Figure 4** illustrates that the premature stop codon was introduced into the *MAT1-2-7* gene into the correct reading frame, ensuring that the gene would be truncated in a similar manner to that of *H. moniliformis*. Furthermore, Southern blot analysis showed that the dDNA construct was only integrated at a single site in the genome.

The success of the protocol was confirmed upon the phenotypic analysis of the mutant strains. In the case of the *MAT1-2-7* disruption experiment, two independent mutant strains were developed. In both isolates, the vegetative radial growth rate was significantly reduced, suggesting a pleiotropic effect of the novel mating gene (**Figure 5**). Furthermore, the mutant isolates were incapable of completing a sexual cycle, producing only immature sexual structures that did not produce sexual spores (**Figure 5**). This was in contrast to wildtype isolates, which completed the entire sexual cycle within a few days of incubation (**Figure 5**).

## FIGURE AND TABLE LEGENDS:

**Figure 1: Choosing a suitable sgRNA candidate.** (A) A suitable sgRNA will only have similarity to the target region of the genome (in this case indicated by the *MAT* locus sequence). (B) A suitable sgRNA will have identical minimal free energy and centroid secondary structures, with the three stem loops and five rings in the primary step loop. Furthermore, the majority of the structure will have high binding probabilities (indicated in dark orange and red) while lower binding probabilities should be seen at the protospacer region (indicated by the black triangles).

**Figure 2: Design, amplification and assembly of the dDNA.** The first and second primer pairs (PP1 and PP2) are used to amplify approximately 800 bp upstream (5') and 800 bp downstream (3') of the gene of interest. The reverse primer of PP1 and the forward primer of PP2 include regions of homology to the hygromycin resistance cassette. The third primer pair amplifies the entire hygromycin resistance cassette. In a stepwise manner, the various amplicons are assembled until the entire dDNA, comprised of the 5' region, the hygromycin resistance cassette and 3' region, is assembled. When transformed into the cell, the dDNA should recombine at the region where the Cas9 enzyme will have been directed to cut, thereby replacing the gene of interest with the hygromycin resistance cassette. PP4 and PP5 can be used to determine if the dDNA has been correctly inserted into the genome at the appropriate location.

**Figure 3: The different cell types important during the protoplast extraction protocol.** (A) Conidia are used as the starting material for the protocol. These conidia are allowed to germinate and grow until they are (B) young germlings. The ideal growth phase of the young germlings are indicated by the two black arrows. Other mycelial strands seen on (B) are too mature for degradation and should not be used. The final step of the protocol is the release of the (C) round protoplasts, indicated by the black, dotted circles. These cells no longer have cell walls and are thus very sensitive to mechanical disruption.

**Figure 4: The successful integration of the TGA stop codon into the *MAT1-2-7* gene of *H. omanensis*.** (A) The full-length *H. omanensis* *MAT1-2-7* gene, with the sgRNA target site indicated by the green arrow. (B) A magnified schematic of the sgRNA target site within the *H. omanensis* *MAT1-2-7* gene. (C) A magnified schematic of a region of the dDNA showing the stop flanked by arms homologous to the *MAT1-2-7* gene of *H. omanensis*. (D) Sanger sequence chromatogram indicating the successful integration of the stop codon into the *MAT1-2-7* gene. Modified from Wilson et al. 2020<sup>21</sup>.

**Figure 5: The phenotypic differences between (A) wildtype isolates and (B) mutant isolates.** The first three images in each panel show the differences in the sexual capabilities of the two isolate types. While the wildtype isolates form mature ascomata during sexual reproduction, complete with the exudation of spores from the tips of the ascomatal necks, the mutant isolates form only immature sexual structures that do not produce any sexual spores. The fourth image in each panel shows the difference in growth rate and morphology of the two

isolate types. While the wildtype isolate grows much faster and with more aerial mycelia, the mutant shows slower and is submerged within the agar. Modified from Wilson et al. 2020<sup>21</sup>.

**Table 1: Degradation of the germling/mycelia solution with lysing enzymes from *Trichoderma harzianum*.** The different enzymes concentrations correspond to different incubation periods, with lower concentrations requiring longer incubations.

## DISCUSSION:

The protocol for the successful transformation of *H. omanensis* and editing of the *MAT1-2-7* gene was demonstrated by introducing an in-frame premature stop codon along with a gene for resistance to hygromycin B<sup>21</sup>. This was achieved using a protein-based version of the CRISPR-Cas9 genome editing system. The experiment entailed the in vitro transcription of the sgRNA, PCR-based assembly of the dDNA and the co-transformation of these two nucleic acids with a commercially available Cas9 enzyme into protoplasts extracted from *H. omanensis*

Unlike other protocols that rely on the availability of many other molecular tools, the protocol described above can be successfully used in species for which the molecular toolbox is still fairly limited<sup>21</sup>. The protocol relies only on an established transformation system and the availability of NGS data, preferably whole genome sequence. While an effective transformation system may take some optimizing in a species for which this is not available, there are many different protocols available for a variety of species. Furthermore, genome data is becoming increasingly available for even the most obscure of species and is becoming easier to generate de novo if it does not already exist.

Given the length of the protocol, there are many steps at which modifications can be introduced and where troubleshooting may be necessary. This is particularly true of the steps that are considered species specific. For example, there are many incubation steps in this protocol that need to be conducted at specific temperatures and for specific lengths of time in order to generate cell types important for the experiment. These steps would thus require species-specific optimization. Where possible, micrographs of the particular cells or growth phases have been provided to assist in transferring this protocol to a different species (Figure 1). The type and concentration of enzymes used to degrade the cell walls of the fungal cells in order to release the protoplasts will also be specific to the species of fungus being studied. In this protocol, only one source of lysing enzymes from is used, while different enzyme combinations are required for the extraction of protoplasts in species like *Fusarium verticillioides*<sup>33</sup>. This step depends entirely on the chemical make of the cell wall and will thus need to be optimized on a species to species basis.

This method is particularly significant to those studying non-model species as there is no reliance on an expression system. A popular method of establishing the CRISPR-Cas9 genome editing system is to express the Cas9 protein, the sgRNA as well as the dDNA from one or two plasmids that are transformed into the cells of choice. In this case, the Cas9 needs to be expressed by a promoter that is capable of high levels of expression in the particular organism being studied. General promoters have been developed for use in filamentous fungi and while

they are not compatible in all species, they do allow for low level expression and can successfully be used to express, for example, antibiotic resistance genes. These promoters, however, often do not allow for high levels of expression and thus cannot be used to express the Cas9 protein. Using a protein-based version of the CRISPR-Cas9 genome editing system overcomes this limitation and allows the sgRNA and dDNA to be co-transformed into the cell with an already produced Cas9 enzyme.

The development of this protein-based system for use in *H. omanensis* came after many unsuccessful attempts at genome editing using both the classical split marker approach as well as the plasmid-based CRISPR-Cas9 system. While efficiencies differ from species to species, the split marker approach has been successfully used with 100% efficiency in species as diverse as *Alternaria alternata*<sup>34,35</sup>, and *C. nicotianae*<sup>36</sup>. In contrast, the efficiency of this system in *H. omanensis* was zero, despite more than 80 independent transformation and integration events. Similarly, the plasmid-based CRISPR-Cas9 system has been successfully used with high efficiencies in *Trichoderma reesei* (>93%)<sup>17</sup> and *Penicillium chrysogenum* (up to 100%)<sup>37</sup>. This is, again, in contrast to this system's usefulness in *H. omanensis*. Sufficient expression of the Cas9 protein was not attainable in *H. omanensis* despite trying a number of potential promoters, including two species-specific promoters predicted from housekeeping genes. Thus, this system could not be used at all. Using the protein-based version of the CRISPR-Cas9 system, however, yielded many independent transformants, two of which harbored the integrated dDNA in the correct location. Furthermore, this experiment was attempted only once and was successful further illustrating the ease at which this system can be used.

Future applications of this protocol include its optimization and use in other species of the Ceratocystidaceae. There is already a wealth of NGS data available for these species<sup>30,38,39</sup> and studies regarding their host specificity<sup>40</sup>, growth rate and virulence<sup>41</sup> have been conducted. These studies can be strengthened by the functional characterization of the genes that are thought to be involved in these processes, research which will now become possible due to the availability of a transformation and genome editing protocol.

In conclusion, thorough investigation into the genes underlying important biological processes in non-model species is becoming more accessible thanks to the availability of easy-to-use genome editing protocols that do not rely on the existence of extensive biological resources and molecular toolkits. Studying non-model species is becoming easier and will allow for the discovery of novel pathways and interesting deviations from the standard biological processes that have been elucidated in model species.

#### ACKNOWLEDGMENTS:

This project was supported by the University of Pretoria, the Department of Science and Technology (DST)/National Research Foundation (NRF) Centre of Excellence in Tree Health Biotechnology (CTHB). The project was additionally supported by Prof BD Wingfield's DST/NRF SARChI chair in Fungal Genomics (Grant number: 98353) as well as Dr AM Wilson's NRF PhD bursary (108548). The grant holders acknowledge that opinions, findings and conclusions or recommendations expressed in this piece of work are that of the researchers and that the

funding bodies accept no liability whatsoever in this regard.

#### DISCLOSURES:

The authors have nothing to disclose.

#### REFERENCES:

1. Ekblom, R., Galindo, J. Applications of next generation sequencing in molecular ecology of non-model organisms. *Heredity*. **107**, 1–15 (2011).
2. Russell, J.J. et al. Non-model model organisms. *BMC Biology*. **15** (55), 1–31 (2017).
3. Kück, U., Hoff, B. New tools for the genetic manipulation of filamentous fungi. *Applied Microbiology and Biotechnology*. **86**, 51–62 (2010).
4. Li, D., Tang, Y., Lin, J., Cai, W. Methods for genetic transformation of filamentous fungi. *Microbial Cell Factories*. **16** (168), 1–13 (2017).
5. Lorito, M., Hayes, C.K., Pietro, A. Di, Harman, G.E. Biolistic transformation of *Trichoderma harzianum* and *Gliocladium virens* using plasmid and genomic DNA. *Current Biotechnology*. **24**, 349–356 (1993).
6. Taylor, P. et al. Transformation of intact *Aspergillus niger* by electroporation. *Bioscience, Biotechnology, and Biochemistry*. **58** (12), 2224–2227 (2014).
7. Dhawale, S.S., Paietta, J. V, Marzluf, G.A. A new, rapid and efficient transformation procedure for *Neurospora*. *Current Genetics*. **8**, 77–79 (1984).
8. Sayari, M., Nest, M.A. Van Der, Steenkamp, E.T., Adegeye, O.O., Marincowitz, S. Agrobacterium-mediated transformation of *Ceratocystis albifundus*. *Microbiological Research*. **226**, 55–64 (2019).
9. Meyer, V. Genetic engineering of filamentous fungi- Progress, obstacles and future trends. *Biotechnology Advances*. **26**, 177–185 (2008).
10. You, B.-J., Lee, M.-H., Chung, K.-R. Gene-specific disruption in the filamentous fungus *Cercospora nicotianae* using a split-marker approach. *Archives of Microbiology*. **191**, 615–622 (2009).
11. Gravelat, F.N., Askew, D.S., Sheppard, D.C. Targeted gene deletion in *Aspergillus fumigatus* using the hygromycin-resistance split-marker approach. *Host-Fungus Interactions*. **845**, 119–130 (2012).
12. Wang, Y., Diguistini, S., Bohlmann, J., Breuil, C. Agrobacterium-mediated gene disruption using split-marker in *Grossmannia clavigera*, a mountain pine beetle associated pathogen. *Current Genetics*. **56**, 297–307 (2010).
13. Wood, A.J. et al. Targeted genome editing across species using ZFNs and TALENs. *Science*. **333**, 307 (2011).
14. Mahfouz, M.M., Piatek, A., Neal, C., Jr, S. Genome engineering via TALENs and CRISPR/Cas9 systems: Challenges and perspectives. *Plant Biotechnology*. **12**, 1006–1014 (2014).
15. Wang, H., Russa, M. La, Qi, L.S. CRISPR/Cas9 in genome editing and beyond. *Annual Review of Biochemistry*. **85** (1), 227–264 (2016).
16. Arazoe, T. et al. Tailor-made TALEN system for highly efficient targeted gene replacement in the rice blast fungus. *Biotechnology and Bioengineering*. **112** (7), 1335–1342 (2015).
17. Liu, R., Chen, L., Jiang, Y., Zhou, Z., Zou, G. Efficient genome editing in filamentous

705 fungus *Trichoderma reesei* using the CRISPR/Cas9 system. *Cell Discovery*. **1**, 1–11 (2015).

706 18. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., Charpentier, E. A  
707 programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*.  
708 **337**, 816–822 (2012).

709 19. Gasiunas, G., Barrangou, R., Horvath, P., Siksnys, V. Cas9–crRNA ribonucleoprotein  
710 complex mediates specific DNA cleavage for adaptive immunity in bacteria. *Proceedings of the*  
711 *National Academy of Sciences*. **109** (39), 2579–2586 (2012).

712 20. Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., Zhang, F. Genome engineering  
713 using the CRISPR-Cas9 system. *Cell*. **8** (11), 2281–2308 (2013).

714 21. Wilson, A.M., Wilken, P.M., Nest, M.A. Van Der, Wing, M.J., Wing, B.D. The novel  
715 *Huntia omanensis* mating gene, *MAT1-2-7*, is essential for ascomatal maturation. *Fungal*  
716 *Genetics and Biology*. **137**, 103335 (2020).

717 22. Miao, J. et al. Characterization of an N-terminal non-core domain of RAG1 gene  
718 disrupted Syrian Hamster model generated by CRISPR Cas9. *Viruses*. **10** (243), v10050243  
719 (2018).

720 23. Roberts, B. et al. Systematic gene tagging using CRISPR/Cas9 in human stem cells to  
721 illuminate cell organization. *Molecular Biology of the Cell*. **28** (21), 2854–2874 (2016).

722 24. Schneider, S., Kirchner, M., Kirchner, M., Schneider, S. CRISPR-Cas: From the bacterial  
723 adaptive immune system to a versatile tool for genome engineering. *Angewandte Chemie*  
724 *International Edition*. **54** (46), 13508–13514 (2015).

725 25. Nødvig, C.S., Nielsen, J.B., Kogle, M.E., Mortensen, U.H. A CRISPR-Cas9 system for  
726 genetic engineering of filamentous fungi. *PLoS ONE*. **10** (7), 1–18 (2015).

727 26. Wang, Q., Cobine, P.A., Coleman, J.J. Efficient genome editing in *Fusarium oxysporum*  
728 based on CRISPR/Cas9 ribonucleoprotein complexes. *Fungal Genetics and Biology*. **117** (March),  
729 21–29 (2018).

730 27. Nagy, G. et al. Development of a plasmid free CRISPR-Cas9 system for the genetic  
731 modification of *Mucor circinelloides*. *Scientific Reports*. **7** (16800), 1–10 (2017).

732 28. Al-Subhi, A.M., Al-Adawi, A.O., Van Wyk, M., Deadman, M.L., Wingfield, M.J.  
733 *Ceratocystis omanensis*, a new species from diseased mango trees in Oman. *Mycological*  
734 *Research*. **110** (2), 237–245 (2006).

735 29. Wilson, A.M., van der Nest, M.A., Wilken, P.M., Wingfield, M.J., Wingfield, B.D.  
736 Pheromone expression reveals putative mechanism of unisexuality in a saprobic ascomycete  
737 fungus. *PLoS ONE*. **13** (3), e0192517 (2018).

738 30. van der Nest, M.A. et al. Draft genomes of *Amanita jacksonii*, *Ceratocystis albifundus*,  
739 *Fusarium circinatum*, *Huntia omanensis*, *Leptographium procerum*, *Rutstroemia sydowiana*,  
740 and *Sclerotinia echinophila*. *IMA Fungus*. **5** (2), 472–485 (2014).

741 31. Wilson, A.M., Godlonton, T., van der Nest, M.A., Wilken, P.M., Wingfield, M.J.,  
742 Wingfield, B.D. Unisexual reproduction in *Huntia moniliformis*. *Fungal Genetics and Biology*.  
743 **80**, 1–9 (2015).

744 32. Sambrook, J., Green, M. *Molecular cloning: A laboratory manual*. Cold Spring Harbor  
745 Laboratory Press. (2012).

746 33. Ramamoorthy, V., Govindaraj, L., Dhanasekaran, M., Vetrivel, S., Kumar, K.K., Ebenezar,  
747 E. Combination of driselase and lysing enzyme in one molar potassium chloride is effective for  
748 the production of protoplasts from germinated conidia of *Fusarium verticillioides*. *Journal of*



749 *Microbiological Methods* (2015).

750 34. Lin, C., Yang, S.L., Wang, N., Chung, K. The FUS3 MAPK signaling pathway of the citrus  
751 pathogen *Alternaria alternata* functions independently or cooperatively with the fungal redox-  
752 responsive AP1 regulator for diverse developmental, physiological and pathogenic processes.  
753 *Fungal Genetics and Biology*. **47** (4), 381–391 (2010).

754 35. Lin, C., Chung, K. Specialized and shared functions of the histidine kinase- and HOG1  
755 MAP kinase-mediated signaling pathways in *Alternaria alternata*, a filamentous fungal  
756 pathogen of citrus. *Fungal Genetics and Biology*. **47** (10), 818–827 (2010).

757 36. Choquer, M. et al. The CTB1 gene encoding a fungal polyketide synthase is required for  
758 cercosporin biosynthesis and fungal virulence of *Cercospora nicotianae*. *Molecular Plant-  
759 Microbe Interactions*. **18** (5), 468–476 (2005).

760 37. Pohl, C., Kiel, J.A.K.W., Driessen, A.J.M., Bovenberg, R.A.L., Nygård, Y. CRISPR/Cas9  
761 based genome editing of *Penicillium chrysogenum*. *ACS Synthetic Biology*. **5** (7), 754–764 (2016).

762 38. van der Nest, M.A.M.A. et al. Draft genome sequences of *Diplodia sapinea*, *Ceratocystis  
763 manginecans* and *Ceratocystis moniliformis*. *IMA Fungus*. **5** (1), 135–140 (2014).

764 39. Wingfield, B.D. et al. Draft genome sequences for *Ceratocystis fagacearum*, *C.  
765 harringtonii*, *Grosmannia penicillata*, and *Huntia bhutanensis*. *IMA Fungus*. **7** (2), 317–323  
766 (2016).

767 40. Fourie, A., Nest, M.A. Van Der, Vos, L. De, Wingfield, M.J., Wingfield, B.D., Barnes, I. QTL  
768 mapping of mycelial growth and aggressiveness to distinct hosts in *Ceratocystis* pathogens.  
769 *Fungal Genetics and Biology*. **131**, 103242 (2019).

770 41. Lee, D.H., Roux, J., Wingfield, B.D., Wingfield, M.J. Variation in growth rates and  
771 aggressiveness of naturally occurring self-fertile and self-sterile isolates of the wilt pathogen  
772 *Ceratocystis albifundus*. *Plant Pathology*. **64** (5), 1103–1109 (2015).

773

Figure 1\_new

**A** sgRNA\_2

GCTGATCGGATCAATACGCAAGG

[Click here to access/download;Figure;Figure\\_1\\_ne](#)

MAT Locus

Scaffold 6542

Scaffold 6175

Scaffold 6498

Scaffold 6454

Scaffold 6527

Scaffold 6485

Scaffold 6424

Scaffold 6419


Scaffold 6342

Scaffold 6115


Scaffold 6070

GCTGATGGTATCAATACGCAAGG  
 TGATGGTATCAATAAGCA  
 GCTGATGGTATCAAT  
 TATCAATACGCAAG  
 TGGTAGCAATACGCAAG  
 TGGTGCTATCAATACGCA  
 TGATGGTATCAAT  
 GCTGATGGTATCA  
 GTATCAATACGCA  
 ATGGTATCAATAC  
 TCAATACGCAAGG  
 GTATCAATACGCA


**B**




Minimal Free Energy  
 Secondary Structure



Centroid  
 Secondary Structure






Conidia



Germlings



Protoplasts

Figure 4












Figure 5

[Click here to access/download;Figure;Figure5.pdf](#)

**A**



**B**



Reaction	Enzyme Concentration	Degradation Time
A	1.250 mg/mL	180 min
B	1.875 mg/mL	180 min
C	2.500 mg/mL	150 min
D	3.750 mg/mL	150 min
E	4.375 mg/mL	120 min
F	5.000 mg/mL	120 min



Name of Material/ Equipment	Company
EcoRI-HF	New England Biolabs, Ipswich, USA
EnGen Spy Cas9 NLS protein	New England Biolabs, Ipswich, USA
Eppendorf 5810 R centrifuge	Eppendorf, Hamberg, Germany
FastStart Taq DNA Polymerase	Sigma, St Louis, USA
GeneJET Gel Extraction Kit	ThermoFisher Scientific, Waltham, USA
HindIII-HF	New England Biolabs, Ipswich, USA
HiScribe™ T7 Quick High Yield RNA synthesis kit	New England Biolabs, Ipswich, USA
Hygromycin B from <i>Streptomyces hygrosopicus</i>	Sigma, St Louis, USA
Infors HT Ecotron Shaking Incubator	Infors AG, Bottmingen, Switzerland
LongAmp Taq DNA Polymerase	New England Biolabs, Ipswich, USA
Malt extract agar, 2% (MEA)	
Malt extract	Sigma, St Louis, USA
Agar	Sigma, St Louis, USA
Malt Extract broth, 1% (MEB)	Sigma, St Louis, USA
Malt Extract broth, 2% (MEB)	Sigma, St Louis, USA
Miracloth	Merck Millipore, New Jersey, USA
Nylon membrane (positively charged)	Sigma, St Louis, USA
Osmotic control medium (OCM)	
Casein Hydrolysate	Sigma, St Louis, USA
Sucrose	Sigma, St Louis, USA
Yeast extract	Sigma, St Louis, USA
Osmotic control medium (OCM) agar	
Agar	Sigma, St Louis, USA
PCR DIG Labeling Mix	Sigma, St Louis, USA
Phusion High-Fidelity DNA Polymerase	ThermoFisher Scientific, Waltham, USA
Plasmid pcb1004	N/A
Presynthesized sgRNA	Inqaba Biotec, Pretoria, South Africa
Proteinase K	Sigma, St Louis, USA
PTC Solution	
Polyethylene glycol 8000	Sigma, St Louis, USA
RNase A	ThermoFisher Scientific, Waltham, USA
RNAfold Webserver	Institute for Theoretical Chemistry, University of Vienna
RNAstructure	Mathews Lab
Sorbitol, 1 M	Sigma, St Louis, USA
STC Buffer	
Calcium chloride	Sigma, St Louis, USA
Tris-HCl pH 8.00	Sigma, St Louis, USA
Sucrose	Sigma, St Louis, USA
<i>Trichoderma harzianum</i> lysing enzymes	Sigma, St Louis, USA
Zeiss Axioskop 2 Plus Ergonomic Trinocular Microscope	Zeiss, Oberkochen, Germany



Catalog Number	Comments/Description
R3101S	
M0646T	Used to assemble the RNP
12032902001	Standard DNA polymerase
K0691	
R3104S	
E2050S	
10843555001	
M0323S	Long-range, high-fidelity DNA polymerase
	20 g ME and 20 g agar in 1 l ddH <sub>2</sub> O
70167-500G	
A5306	
70167-500G	2 g ME in 200 ml ddH <sub>2</sub> O
70167-500G	4 g ME in 200 ml ddH <sub>2</sub> O
475855	
11209299001	
	0.3% yeast extract, 20% sucrose, 0.3% casein hydrolysate
22090	
84097	
Y1625	
	Osmotic control medium (OCM) + 1% agar
A5306	
11585550910	
F-530XL	High fidelity DNA polymerase
N/A	From: Carroll et al., 1994
	Ordered as an synthesized dsDNA with specified sequence
P2308	
	30% polyethylene glycol 8000 in STC buffer from above
1546605	
12091021	
N/A	<a href="http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi">http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi</a>
N/A	<a href="https://rna.urmc.rochester.edu/RNAstructureWeb/Servers/Predict1/Predict1.html">https://rna.urmc.rochester.edu/RNAstructureWeb/Servers/Predict1/Predict1.html</a>
1617000	182.17g sorbitol in 1 l ddH <sub>2</sub> O
	20% sucrose, 50 mM Tris-HCl pH 8.00 and 50 mM CaCl <sub>2</sub>
429759	
10812846001	
84097	
L1412	

## **Response to Editor's and Reviewers' Comments and Suggestions**

Please note that the page and line numbers referred to in our responses represent those found in the newly submitted manuscript.

### **Editor:**

1. **The editor asked that the manuscript be thoroughly proofread and that all formatting be done according to JoVE guidelines.**

This has been done.

2. **The editor asked that at least 6 keywords are included.**

A total of 7 keywords have been included in the revised manuscript (Lines 22 - 28).

3. **The editor asked that all commercial language be removed from the manuscript and instead be referenced in the Table of Materials and Reagents.**

All the commercial language has been removed from the manuscript and is instead referenced in the Table of Materials.

4. **The editor asked that we ensure that the protocol is written in imperative tense, contains only action items and be made up entirely of discrete steps.**

The protocol is written in imperative tense and is made up of discrete steps.

5. **The editor asked that we ensure that each step of the protocol contained only 2-3 actions per step.**

Each step of the protocol includes only 2-3 actions.

6. **The editor asked that include exactly how each step will be performed, including "button clicks" where necessary.**

The only button clicks in this protocol are specific to the software used – CLC Main workbench. As we have been asked not to refer to any specific company or use any commercialized language, we have not included any of these in the protocol.

7. **The editor asked us to specify what the required minimal energy was from Step 2.2.2.2.**

The term "minimal energy" refers to one of the two structures that the program produces from the RNA sequence provided- the minimal free energy structure and the centroid structure. While the program does give the actual energy amount, this is less important than the predicted structures it produces, and it is the structures that should be interrogated. A sentence has been added in a NOTE to address this (Lines 301 - 305).

- 8. The editor asked us to specify what the expected band sizes from our experiment would be from Step 3.3.4.**

The expected band sizes will depend on the particular PCR product produced in the preceding steps as well as where in that PCR product the target region is found. In the case of our specific experiment, these bands sizes were 135 bp and 737 bp, however, this particular result is not relevant to a different experiment and we thus believe it does not need to be included here.

- 9. The editor stated that the total protocol should not exceed 10 pages and that 2.75 pages should be highlighted for the video.**

The protocol is just over 8 pages and approximately 2.75 pages have been highlighted for the video.

- 10. The editor asked that we include explicit copyright permission to reuse images from a previous publication.**

The license is attached in the resubmission.

### **Reviewer 1:**

- 1. The reviewer was concerned that we used the terms “functional characterization” and “genome editing” interchangeably and thus made parts of the text misleading.**

Many instances of “functional characterization” have been removed from the manuscript while dealing with other comments/suggestions from all three of the reviewers and the editor. Many of these particular examples included places where the term was used in place of “genome editing”. When the term “functional characterization” still exists in the manuscript, it cannot be mistaken to mean “genome editing”. All instances of “genome editing” that are present in the manuscript refer to the specific act of genome editing and thus cannot be mistaken to mean “functional characterization”.

- 2. The reviewer was concerned that the text is written as if the protocol could be used in other fungal species.**

While the manuscript describes the development of this protocol in *Huntia omanensis*, we believe that a very similar protocol can be followed for many other filamentous fungi. We have written the manuscript in such a way that authors working on different species could use it as a template for the development of their own protocols.

**3. The reviewer was concerned that we had not referenced any articles in which fungi had been transformed or been subjected to genome editing.**

In order to address this concern, we have included a number of extra references that include articles in which fungi are subjected to transformation and/or genome editing. These include:

- Different transformation methods: Biolistics (*Trichoderma harzianum*, Line 85), Electroporation (*Aspergillus niger*, Line 85), Lithium-acetate (*Neurospora crassa*, Line 86) and *Agrobacterium*-mediated (*Ceratocystis albifundus*, Line 88)
- Split marker-based genome editing of *Cercospora nicotianae*, *Aspergillus fumigatus* and *Grosmannia clavigera* (Lines 103 - 104)
- TALENs-based genome editing of *Magnaporthe oryzae* (Lines 120 - 121)
- CRISPR-Cas9-mediated Genome editing of *Aspergillus nidulans* and *A. aculeatus* (Lines 153 - 155), *Fusarium oxysporum* (Line 175) and *Mucor circinelloides* (Lines 175 - 176)

**4. The reviewer suggested changing the title to better describe the manuscript presented.**

A new title has been included (Line 5).

**5. The reviewer suggested an extra two key words .**

These two key words/phrases were “RNP” and “*Huntia omanensis*” and have been included (Lines 24 & 28).

**6. The following minor changes were made to the summary based on suggestions by the reviewer:**

- Line 39. Delete "promising"
- Line 46. Replace “protocols” with “gene editing strategies”
- Line 50 - 52. Delete "The limitations of the system are similar to those of previously used protocols" and replace by “Similarly to other genome editing strategies, CRISPR-Cas9 based methods require efficient and effective transformation protocols...”
- Line 55. Include fungal examples
- Line 57 - 58. Replace "functional characterization" by "study"
- Line 59. End the sentence with "among others"
- Line 60 - 61. Replace "functional characterization" by "truncation". (In this case, the reviewer suggested the word “deactivated”. However, we believe that “truncation” better described what was done.)

**7. The reviewer asked that we rephrase a sentence starting “Genome...”**

The sentence was rephrased (Lines 43 -45).

**8. The reviewer asked that we rephrase a sentence starting “This kind...”**

The sentence was rephrased (Line 69).

**9. The reviewer was concerned that a particular sentence implied that elucidating the function of genes is possible simply by mutant generation and phenotypic analysis.**

This concern was addressed by rewording the sentence to indicate that only partial characterization is possible using this method (Lines 78 - 80). The sentence was further changed to indicate that this is not the only method of functional characterization as indicated by Reviewer 2 (Point 3).

**10. The reviewer asked that we delete a sentence that included the phrase “In contrast to the availability of many different transformation protocols”.**

In this case, we disagree with the reviewer who has said that we should delete this sentence as there are “only a few strategies” available for the transformation of filamentous fungi. In the previous paragraph, we have illustrated at least five different strategies. We have thus not deleted this sentence (Lines 94 - 95).

**11. The reviewer asked that we rewrite and restructure a paragraph to include the principles behind genomic modifications, such as the use of the endogenous DNA repair pathways.**

The section that needed to be rewritten and restructured was previously made up of a single paragraph. This has been broken down into three different paragraphs, each dealing with a different type of DNA modification (Lines 94 - 148). The principles behind each has been detailed.

**12. The reviewer asked that we rewrite a section of the manuscript to illustrate that HD-mediated gene knockouts are still done by many labs.**

This section has been altered in response to Point 11 above and now includes extra information that was not previously here. We have also included three different examples of filamentous fungi in which HD-mediated knockouts were successfully conducted.

**13. The reviewer asked that we described the principles behind genome editing technologies like TALENS and ZFNs and also include a list of fungi where these sorts of systems have been established.**

A new paragraph has been included in the introduction to address this request (Lines 108 - 121). These systems have not widely been used in fungi, but we were able to provide an example.

**14. The reviewer asked that we include a sentence stating that Cas9 can be introduced into a host cell in either DNA, RNA or protein form and to briefly highlight the advantages of using each.**

We have addressed this suggestion by including a new paragraph (Lines 150 - 176) in the introduction that includes information regarding the use of Cas9 in DNA, RNA and protein form as well as the various advantages and disadvantages of these systems.

**15. The following minor changes were made to the introduction based on suggestions by the reviewer:**

- Line 67: Delete "we've been researching for decades"
- Line 74: Replace "these" by "many"
- Line 75: Replace "data is easy" by "data is relatively easy"
- Line 83: Update reference by including 10.1186/s12934-017-0785-7
- Line 101: Delete "in theory"
- Line 148: Include references for the two applications.
- Lines 190 - 191: Highlight that no transformation protocol had been established for the organism
- Line 203: "The protocol below details the transformation of *H. omanensis* and the truncation of...

**16. The reviewer ask that we remove any commercial language.**

This was addressed in response to a comment from the editor.

**17. The reviewer asked that "Extraction of protoplasts" section of the protocol should be moved to a different place in the manuscript.**

To address this request, the relevant section was moved (Lines 413 - 482). This had the effect of changing the order of Protocol Steps 1 – 4. These have been renumbered accordingly (Lines 270 - 628).

**18. The reviewer asked that we clarify why we chose not to use any homology search programs to identify potential protospacer sequences.**

Identification of the sgRNA target sequences was conducted manually, searching for "NGG" sequences within the gene of interest. While online tools are available, the gene region we were targeting was short enough (only 468 bp) to conduct this search manually. We have included a NOTE in the protocol that deals with this (Lines 277 - 278).

**19. The reviewer asked that we explain why we used the RNAfold webserver specifically and asked us to include other examples of software that could be used**

We used this tool because the RNAfold webserver is an easy to use, online tool that provides results that are easy to interpret. There are other online tools, such as

RNAstructure, which give similar results. There are also programs that can be downloaded for this purpose, which we have chosen not to include as they are less user friendly and given similar results to the online tools. In response to the editor who asked that we not include “commercial language” in the manuscript, we have changed this particular step to state that an “RNA secondary structure prediction tool” should be used (Lines 295 - 296) and we have included RNAfold and RNAstructure as examples in the Table of Materials instead.

**20. The reviewer asked that we move the section detailing the synthesis of the sgRNA to later in the manuscript.**

The particular section that the reviewer is referring to is Step 1.3 (Lines 310 - 331) in the protocol where, after designing the sgRNA, the construct is synthesized using a kit. The reviewer is asking that this particular step be moved later in the protocol as it is followed with steps such as “add a G to the 5’ end” and “add T7 sequence”, which looks as though this is part of the “sgRNA design”. However, the steps that follow Step 1.3 are only relevant if this step is actually conducted using a kit. If the construct is simply ordered pre-synthesized, these steps are no longer relevant. In order to address the confusion, we have added a note stating this (Lines 314 - 316).

**21. The reviewer asked that we include a new figure including all the relevant DNA sequences to better explain the synthesis of the sgRNA and scaffold.**

This particular step uses a kit that is referred to in the Table of Materials and the sequences and steps that need to be conducted will depend on the manufacturer of the kit. A figure with this kind of information will thus only be specific to one kit. Furthermore, most commercially available kits will include their own figures that illustrate this process in their manuals. We have thus decided not to include this extra figure and feel it won’t be helpful to readers of this manuscript.

**22. The reviewer asked that we include information on selecting the correct restriction enzymes for use in the Southern blot experiment.**

The information that this reviewer is requesting is common and standard to all Southern blots conducted for the purpose of confirming only a single introduction of the exogenous DNA into a genome. This particular information is detailed in the referenced protocol (Reference 32) that is included in this section.

**23. The following minor changes were made to the protocol based on suggestions by the reviewer:**

- Line 218: Replace "falcon" by "centrifuge"
- Line 429: Discard supernatant
- Line 433: Figure 1A
- Line 231: Replace "falcon" by "centrifuge"

- Line 445: Discard supernatant
- Line 450: Replace "conidia" by "germlings"
- Line 451: Figure 1B
- Line 476: Figure 1C
- Line 302: Figure 2B
- Line 305: Figure 2B
- Line 345: Included a NOTE point saying that this step is optional
- Lines 605 - 614: Be more clear regarding the sealing of the plates
- Line 628 - 629: Delete "using a two...."

**24. The reviewer was concerned that the first three paragraphs of the representative results contain information better suited to the discussion and asked that we either rephrase these paragraphs or integrate them into the discussion.**

To address this concern, we have moved the entire first paragraph of the representative results to the discussion (Lines 739 - 744). We kept the second and third paragraphs in this section as they directly detail the results of our experiments and refer to the figures that illustrate these results (Lines 746 - 768).

**25. The reviewer asked us that we highlight that the transformation experiment was successful.**

The first sentence of this paragraph was altered to indicate that both transformation and gene editing were successful (Lines 739 - 740).

**26. The reviewer asked that we rewrite the discussion to focus on the protocol as it is used in *H. omanensis*.**

In JoVE's instruction to authors document, it states that the discussion section should focus specifically on the protocol, which steps are critical, where modifications and troubleshooting may be necessary, what limitations exist, the significance of this method and what the future applications may be. We believe that we have followed these specific instructions. Furthermore, the relevance of this particular protocol is not that it has been done in *H. omanensis*, but that it can be developed for use in many other non-models species as well. Rewriting this section to only include the protocol used in *H. omanensis* would thus limit its usefulness to other researchers.

**27. The reviewer was also concerned that the discussion read as though this manuscript is the first to use the protein-based version of the CRISPR-Cas9 genome editing system.**

A previous comment from this reviewer asked that we include a new paragraph in the introduction that includes information regarding the use of Cas9 in DNA, RNA and protein form (Lines 150 - 176). In addition to adding this information, we also added experimental examples of each of these. In particular, we included two references that show the use of the protein-based system in two other fungal species. We believe this



section has made it clear that our manuscript is not the first to use this particular version of the CRISPR-Cas9 genome editing system.

**28. The reviewer suggested that we include a section discussing the genome editing efficiency of this system in *H. omanensis* to other systems in other filamentous fungal species.**

A paragraph has been added to the discussion (Lines 783 - 797) detailing the efficiency of the split marker approach and the plasmid-based CRISPR-Cas9 approach in other filamentous fungi and comparing this information to similar information available from *H. omanensis*.

**Reviewer 2:**

**1. The reviewer was concerned that the summary was not a clear reflection of the rest of the manuscript.**

We agree with the reviewer and have thus reworded the second part of the summary to better summarize the content of the manuscript (Lines 31 - 36).

**2. The reviewer was concerned that the abstract did not reflect what is in the rest of the manuscript.**

The abstract was written in line with the JoVE instructions to authors and focuses “*on the method being presented rather than the results*”. It also includes a “*statement about the purpose of the method*” and a “*detailed overview of the method and a summary of its advantages, limitations, and applications*”. We have thus not changed the original abstract.

**3. The reviewer was concerned about a particular sentence that they considered “too sweeping”.**

A similar concern was raised by Reviewer 1 in Point 9. This sentence was reworded to state that these transgenic approaches *can* be used, rather than that they were *exclusively* used (Lines 78 - 79).

**4. The reviewer asked that we deleted a paragraph from the introduction that included background about the use of fungi as model species.**

This was done (Lines 178 and 186).

**5. The reviewer asked that we delete a section in the discussion that included information regarding the use of Cas9 in its protein form.**

This particular section discusses the advantage of using Cas9 in its protein form rather than in DNA form (Lines 770 - 781). We used this method as the successful implementation of the CRISPR-Cas9 system relies on high levels of expression of the Cas9 enzyme, something that could not be achieved in our species of interest. This is a common problem in non-model species, where species-specific promoters have not yet been identified and experimentally confirmed. The reviewer suggested that this explanation "makes no sense" because we still required expression of the hygromycin resistance cassette to complete the experiment. While this is true, the selectable marker only needs to be expressed at very low levels to be effective and thus even a general fungal promoter is usually sufficient. We have thus not deleted the section and instead have reworded certain parts to make its relevance clear (Lines 775 - 779).

**6. The reviewer asked that we include the following edits:**

- Line 55: another model organism where CRISPR-Cas9 has been used is *Saccharomyces cerevisiae*
- Line 66: "wide variety of biological"
- Line 69: "These kind of data"
- Line 196: "isolates of the closely"
- Line 318: delete "wear gloves and"
- Lines 645 - 647: delete "and thus are only predictions"
- Line 809: delete "followed up and"

**Reviewer 3:**

**1. The reviewer asked that we include model fungi in the examples.**

As per both Reviewer 1 and 2, we have included *Saccharomyces cerevisiae* as a fungal example (Line 55).

**2. The reviewer asked that we include a section detailing why the plasmid-based CRISPR-Cas9 genome editing system was unsuccessful in *H. omanensis*.**

In response to comments from a previous reviewer, we have included a section in the introduction dealing with the disadvantages of using a DNA-based system (Lines 157 - 162). We have also included a paragraph in the discussion regarding the use of non-protein systems in *H. omanensis* and why they were not successful (Lines 750 – 777). These paragraphs explain why the plasmid-based system was unsuccessful in *H. omanensis*.


**3. The reviewer asked whether we used online web tools for identifying the sgRNA target sequences.**

Dealt with previously- see Point 18 from Reviewer 1.


**4. The reviewer asked that we include the following edits:**

- Lines 416: Include the size of the mycelia-covered agar block
- Lines 427 & 466: State that the materials were sterile
- Line 436: Indicate how much of the conidial suspension was used in this step
- Line 450: Replace “conidia” with "germlings"
- Line 457: Include what the contained the digestion/lysis was done in
- Lines 478 - 480: Include the how the concentration of protoplasts was quantified
- Line 476: Replace “conidia” with "protoplasts"


## Protoplast Extractions




## sgRNA Design & Synthesis




## dDNA Design & Synthesis




## Transformations & Selection




## Single Copy Analysis



## Stability Testing



## PCR Confirmation



## Phenotypic Screening

